×
Home Current Archive Editorial board
News Contact
Review paper

Warfarin should not be used for thromboprohylaxis in elective major orthopaedic surgery: a Croatian perspective

By
Robert Kolundžić Orcid logo ,
Robert Kolundžić
Contact Robert Kolundžić

Department of Trauma Surgery, University Hospital Centre “Sestre Milosrdnice”, Zagreb, Croatia

School of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia

Marijana Šimić Jovičić ,
Marijana Šimić Jovičić

Department of Orthopaedics, Children’s Hospital, Zagreb, Zagreb, Croatia

Maja Ðinkić ,
Maja Ðinkić

Department of Orthopaedic Surgery, Karaborg Hospital, Lidkoping, Lidkoping, Sweden

Tadija Petrović ,
Tadija Petrović

Department of Trauma Surgery, University Hospital Centre “Sestre Milosrdnice”, Zagreb, Croatia

Tomislav Crnković ,
Tomislav Crnković

School of Medicine, Josip Juraj Strossmayer University, Zagreb, Croatia

Department of Orthopaedic and Trauma Surgery, County General Hospital, Požega, Croatia

Vladimir Trkulja
Vladimir Trkulja

Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia

Abstract

Aim
To identify modes of venous thromboembolism (VTE) prophylaxis in patients undergoing elective major orthopaedic surgery (total hip or knee arthroplasty, THA/TKA) at a single university-associated hospital in Croatia.
Methods
A retrospective analysis of consecutive patients subjected to THA or TKA over a two-year period (2014-2015) with a focus on anticoagulation during the first 15 post-surgical days (period of highest VTE risk).
Results
Of 603 identified patients three (0.5%) were not anticoagulated (haemophilia) and others received perioperative doses of low molecular weight heparins (LMWH). Overall, 228 (37.8%) patients received prophylaxis not involving warfarin, and 372 continued with short-term LMWH with switching to warfarin. They contributed a total of 1218 international normalized ratio (INR) values (median=3, range=1-8). These were consistently below the target INR range across the observed period. Between post-surgical days 6 and 15 (after the initial titration), 438 values were taken in patients treated with LMWH+warfarin and 92.7% were below, and only 6.8% within the target range; 580 values were taken in patients already switched to warfarin, 74% were below and only 25% within the range.
Conclusion
The prevailing mode of VTE prophylaxis was in a clear contrast to (then) actual professional guidelines, with inadequate monitoring and poor anticoagulation. There is no reason to expect a substantially different situation at other institutions across the country. The prevailing practice of VTE prophylaxis in major orthopaedic surgery in Croatia should be promptly abandoned and updated in agreement with the current state of the art.

References

1.
Kolundžić R, Orlić D. Forty years of total hip replacement in Croatia at the department of orthopedic surgery Zagreb -orthopedic surgery of the 20 th century. Lijec Vjesn. 2011. p. 343–51.
2.
Falck-Ytter Y, Francis C, Johanson N, Curley C, Dahl O, Schulman S, et al. American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients. Antithrombotic therapy and prevention of thrombosis 9 th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012.
3.
Barnes G, Kaatz S, Golgotiu V, Gu X, Leidal A, Kobeissy A, et al. Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). J Thromb Thrombolysis. 2013. p. 10–4.
4.
Nordstrom B, Kachroo S, Fraeman K. Warfarin prophylaxis in patients after total knee or hip arthroplasty -international normalized ratio patterns and venous thromboembolism. Curr Med Res Opinion. 2011. p. 1973–85.
5.
Dubravčić M, Cukon P, Car S, Puljević D, Trkulja V. Croatia needs a registry of patients undergoing direct current cardioversion for persistent atrial fibrillation/ flutter. Croat Med J. 2016. p. 403–5.
6.
Trkulja V. Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date. Drug Health Patient Saf. 2016. p. 25–38.
7.
Trkulja V, Kolundžić R. Rivaroxaban vs. dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J. 2010. p. 113–23.

Citation

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.